Amgen Lifts 2026 Outlook on Repatha Gains
The drugmaker reported third-quarter sales up 8%, led by its cholesterol drug Repatha and other products.
Updated on Nov. 3, 2026 in Healthcare
Live Poll
Do you think new weight-loss drugs will be affordable for people like you?
Amgen reported third-quarter 2026 sales rising 8%, with adjusted earnings up 14% to $6.45 per share, beating analysts' expectations of $5.79. The company raised its full-year 2026 adjusted earnings outlook to $22.90 to $23.70 per share.
Why it matters
The results show growth from newer drugs offsetting declining sales of Prolia as patent expirations bring competition. Amgen's pipeline, including its MariTide weight-loss candidate, positions the company in a potentially large obesity drug market.
Amgen's quarterly revenue reached $10.4 billion, above the $10.1 billion Wall Street average, while Uplizna sales rose 191% to $451 million and Prolia sales fell 45% to $632 million. Initial Phase 3 MariTide results remain pending until next year.
The players
Amgen
Amgen is a large American biotechnology company based in California that develops and sells treatments for conditions including cardiovascular disease, osteoporosis and rare immune disorders.
The details
Repatha, a PCSK9 cholesterol drug given monthly or every two weeks by injection, drove much of the quarter's growth, with Evenity sales up 39% to $751 million. Amgen's net earnings per share rose 19% to $7.08 for the period.
Timeline
Third quarter of 2026: Amgen reports sales rising 8%.
April 2026: The FDA proposes withdrawal of Tavneos, citing effectiveness and data concerns.
Next year: Initial Phase 3 MariTide trial results are expected.
Market Landscape
Repatha's 37% sales growth shows the PCSK9 injectable class continuing to take share in cholesterol treatment. Amgen's MariTide, which may be dosed as infrequently as four times a year, is positioned against a weight-loss market that some analysts estimate could reach $150 billion annually within a decade.
For patients, Repatha's injection schedule of monthly or every-two-weeks dosing is the current benchmark, while MariTide's potential quarterly-or-less dosing could change how long-term obesity treatment is administered. Price and coverage effects for U.S. patients are not addressed in the reported results.
The takeaway
Newer drugs can offset patent-driven declines in older products, as Amgen's results show with Repatha and Uplizna replacing lost Prolia revenue. Investors and patients alike will be watching next year's MariTide data for signs of how the company's pipeline matures.
What happens next
Initial results from Amgen's Phase 3 MariTide trials are expected next year.
Further reading
For more on the sector, see Healthcare coverage of drugmakers and pharmaceutical markets.
Live Poll
Do you think new weight-loss drugs will be affordable for people like you?
